In another study, administration of GM1 resulted in smaller α-synuclein aggregates in vivo, in a rat α-synuclein model of PD (Schneider et al., 2019), likely due to a direct effect of GM1 on α-synuclein folding and aggregation. The gene discussed is SNCA; the disease is Parkinson disease.